Li MX, Tu HX, Yin MC. Meta-analysis of outcomes from drug-eluting stent implantation in infrapopliteal arteries. World J Clin Cases 2023; 11(22): 5273-5287 [PMID: 37621588 DOI: 10.12998/wjcc.v11.i22.5273]
Corresponding Author of This Article
Hai-Xia Tu, MM, Chief Physician, Department of Vascular Surgery, Beijing Fengtai You'anmen Hospital, No. 199 You'anmenwai Street, Beijing 100069, China. haixia_tu2023@163.com
Research Domain of This Article
Peripheral Vascular Disease
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Aug 6, 2023; 11(22): 5273-5287 Published online Aug 6, 2023. doi: 10.12998/wjcc.v11.i22.5273
Meta-analysis of outcomes from drug-eluting stent implantation in infrapopliteal arteries
Ming-Xuan Li, Hai-Xia Tu, Meng-Chen Yin
Ming-Xuan Li, Hai-Xia Tu, Meng-Chen Yin, Department of Vascular Surgery, Beijing Fengtai You'anmen Hospital, Beijing 100069, China
Author contributions: Li MX designed the study; Li MX and Tu HX performed the article search, data extraction, and evidence quality assessment; Li MX and Yin MC performed the risk of bias assessment of the studies; Li MX performed the data analyses and manuscript writing; Tu HX reviewed the article independently and made minor revisions after consultation with Li MX; All the authors read and gave final approval of the version to be submitted; Tu HX is the guarantor of the review.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest to report.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Xia Tu, MM, Chief Physician, Department of Vascular Surgery, Beijing Fengtai You'anmen Hospital, No. 199 You'anmenwai Street, Beijing 100069, China. haixia_tu2023@163.com
Received: May 5, 2023 Peer-review started: May 5, 2023 First decision: July 3, 2023 Revised: July 7, 2023 Accepted: July 17, 2023 Article in press: July 17, 2023 Published online: August 6, 2023 Processing time: 90 Days and 3.4 Hours
ARTICLE HIGHLIGHTS
Research background
Whether accompanied with femoropopliteal inflow disease or not, infrapopliteal artery disease (IPAD) is the primary cause of critical limb ischemia. In the past few decades, minimally invasive percutaneous transluminal angioplasty (PTA) with or without bare metal stent implantation (BMSI) has been widely used.
Research motivation
However, although this treatment has satisfactory technical success rate, it still has a significantly high risk of clinical failure caused by lesion restenosis even in the short term.
Research objectives
In order to more accurately evaluate the efficacy of drug-eluting stents (DES) implantation for IPADs, we performed this systematic review and meta-analysis.
Research methods
After extensive retrieval of major databases, the hazard ratio (HR) is used as the outcome measure for extraction or conversion, and the meta analyses for multiple outcomes of interest were performed.
Research results
Five randomized controlled trials and three cohort studies involving 2639 participants totally were included. Compared with the control arm (PTA and BMSI), the HR values of the DES implantation on all- cause death -free survival and major amputation -free survival were not statistically significant (P > 0.05), but the HR values on target lesion revascularization -free survival, adverse event -free survival, and primary patency -survival were 2.65 (95%CI: 1.56-4.50), 1.57 (95%CI: 1.23-2.01), and 5.67 (95%CI: 3.56-9.03), respectively.
Research conclusions
In our conclusion, DES is a good option for IPADs to maintain efficacy for a long time.
Research perspectives
DES is a highly anticipated therapeutic device. We believe that there will be more and more randomized controlled trials about its application for IPADs in the future.
